Biopsy Guidance System Market is projected to reach a valuation of US$ 2 Billion by 2032

Patients are increasingly preferring minimally invasive surgical procedures in order to avoid conventional surgical complications and side-effects, promoting sales of biopsy devices, leading to the growth of the biopsy devices globally. In addition to enabling the accurate diagnosis, a biopsy device assures minimal patient discomfort and trauma. This is identified to be a major factor impacting the popularity of biopsy, and biopsy device thereby.

Key Opportunities for Manufacturers and Suppliers:

• Developing economies present lucrative, untapped markets for biopsy device.
• Growing adoption of hybrid imaging technology will underpin new growth opportunities.
• Following massive consumption by hospitals, demand for biopsy device from specific oncology centers and research institutes will prompt at multiple opportunities in near future.
• Surging demand for minimal invasive breast biopsy highlights lucrative opportunities that lie in the breast cancer sector.
• Increasing adoption of biopsy device by oncologists will generate several revenue generation opportunities in the disease monitoring sector.

Supported by increasing discretionary funding for cancer research, growing government expenditure for healthcare and favorable reimbursement scenario (especially in the U.S.) will collectively elevate the revenue sales of the global biopsy device market. Collaborations between various government and private companies, fuelled by increasing awareness about disease diagnosis and monitoring, will further elevate the market growth in near future.

Get Latest Sample Copy @
https://www.futuremarketinsights.com/reports/sample/rep-gb-1192

M&A and Technological Upgrades Remain at the Forefront

A majority of key players in the global biopsy device market are currently focusing on providing innovative biopsy tests and technological upgrades. Mergers, acquisitions, and partnerships with diagnostic laboratories will help to strengthen their presence in the global market.

Among the top companies, Becton, Dickinson and Company is concentrating on innovative, cost-effective product development, whereas Hologic, Inc. is targeting manufacture and sales of biopsy devices, especially for breast cancer surgeries. Other notable players include Boston Scientific Inc., C. R. Bard, Inc., B. Braun Melsungen AG, Cook Medical, INRAD Inc., and PLANMED OY.

Argon Medical, one of the promising new entrants, is expanding its product portfolio and collaborating with established players, whereas for Devicor Medical Products Inc., M&A remains the key strategy.

North America Remains the Most Lucrative Market

North America will remain the dominant market and is expected to surpass US$ 882 Mn by 2031 end, accounting for over 33% share of the market. Western Europe is expected to remain the second largest market for biopsy device, crossing a value of US$ 683 Mn by the end of 2031, capturing over 26% share of the market.

APEJ, with around 14% market value share in 2031, reaching a valuation of around US$ 370.0 Mn by the end of forecast period. MEA will register the fastest CAGR of 7.3%, followed by APEJ and Latin America with the respective CAGRs of 7.1% and 6.5% over 2021-2031. North America, Europe, and Japan will see moderate growth over the forecast period.

Biopsy Needles To Remain Top-selling Product Category

By product type, needles will remain dominant with over 36% share of the market value in 2031, whereas guns will represent the second largest sub-segment with over 26% market value share in 2031. With growing significance of early diagnosis of breast biopsy, guidance system segment is estimated to gain around 222 BPS in its market share by 2031 over 2021. Stereostatic X-ray guided biopsy will drive the guidance system segment through to 2031. Reagents and kits will witness moderate consumption.

Ask from Market Research Expert @
https://www.futuremarketinsights.com/ask-question/rep-gb-1192

Medical Diagnostics Monopolize Application Segment

Based on application type, medical diagnostics will continue to hold a dominant share of over 61% by 2031 end, in terms of revenues. Scientific research, accounting for the rest, will witness an impressively growing CAGR of 6.9% over 2021-2031. This segment is expected to reach beyond US$ 1,008.0 Mn in 2031.

Hospitals Remain Largest End-use Consumer

By end-user, hospitals will continue to contribute nearly 50% share to the market value by 2031 end. This end-use segment will witness a robust CAGR of 8.2%. Diagnostic centres will account for over 23% in 2031 with a slight decline over 2021-2031, whereas specialised oncology centres are anticipated to expand at a CAGR of 6.1% during 2021-2031.

Biopsy Device Market – Market Segmentation

By Product Type:

• Guidance System
  • Stereotactic X-Ray Guided Biopsy
  • Ultrasound Guided Biopsy
  • MRI Guided Biopsy
• Needles
  • Core Needles
  • Fine Aspiration Needles
• Guns
• Reagents and Kits
• Others (Brushes, Curettes and Punches etc.)

By Application:

• Medical Diagnosis
• Scientific Research

By End Use:

• Hospital
• Specialised Oncology Centres
• Diagnostic Centres
• Research Institutes

Request Customization @ 
https://www.futuremarketinsights.com/customization-available/rep-gb-1192

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• MEA